{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Suzetrigine: A New Analgesic Approved by the FDA - Vol. 40, No. 9

Activity Steps

1 Activity
2 Take Test 3Certificate

Description

Method of Participation in the Learning Process/Evaluation Method

Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form.

Getting the Most out of the Activity

As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed.

While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Describe the mode of action of suzetrigine and its current uses.
  2. Differentiate between opiates and opioids.
  3. Identify causes and effects of the opioid crisis.

Disclosures

The author, faculty, and staff have no relevant financial relationship with any ineligible organizations regarding this educational activity

Price: $49.00

Credits:

  • ACCME 1.5 CME

Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Planner
Professions: Physician
Test Code: TPM0425
Published: April 2025
Expires: 3/31/2027
Sources: Topics in Pain Management
Required Passing Score: 7/10 (70%)
Authors: Elizabeth A.M. Frost, MD
Categories: Pain Management
Specialties: Anesthesiology, Internal Medicine, Pain Management
Topics: Opiates and Opioids , Suzetrigine